Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.

Br J Dermatol · 2021 · PMC8247037 · PMID 32969489

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Comparison of the two doses showed a numerical trend towards higher responses with 2 mg kg −1 vs. 4 mg kg −1 in the treatment of AD signs and symptoms in both the phase IIa and OLE studies.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.